Home/Pipeline/Remyelination Program

Remyelination Program

Multiple Sclerosis

Pre-clinicalActive

Key Facts

Indication

Multiple Sclerosis

Phase

Pre-clinical

Status

Active

Company

Progentos Therapeutics

About Progentos Therapeutics

Progentos Therapeutics is an early-stage biotech targeting a significant unmet need in multiple sclerosis (MS): repairing existing damage. Unlike approved immunomodulatory therapies that slow progression, Progentos aims to directly stimulate remyelination by activating oligodendrocyte progenitor cells (OPCs) through a novel, proprietary small-molecule approach. The company is in the pre-clinical stage, having identified a novel target and new chemical entities that show compelling remyelination in preclinical models, positioning it as a potential leader in regenerative neurology.

View full company profile

Therapeutic Areas

Neurology Multiple Sclerosis

Other Multiple Sclerosis Drugs

Drug	Company	Phase	Status
Mimotopes-003	Mimotopes	Preclinical	Active
SPU-16	Silo Pharma	Preclinical	Research
Electroceutical® Therapy	Endonovo Therapeutics	Research	Active
IMX39	Imunexus Therapeutics	Preclinical	Active
BTK allosteric inhibitor	Acellera	Pre-clinical	Early Hit
CLS12311	Cellerys	Phase 2	Active
Interferon-beta variants	Heligenics	Pre-clinical	Active
G-NK cells	Indapta Therapeutics	Phase 1	Active
MS Biomarker Research	Rune Labs	Research	Active
AVT001	Avotres	Phase 2b	Active
Undisclosed MS Program	Astoria Biologica	Pre-clinical	Active
PV-3212	Provid Pharma	Pre-clinical	Active